GSK Share PerformanceMore
|52 week high||1,745.5 11/10/16|
|52 week low||1,277.5 14/12/15|
|52 week change||164.0 (12.48%)|
|4 week volume||198,944,340 13/11/16|
Latest News« previous» nextMore
09/12/2016 - 11:46 Money Observer
Woodford Patient Capital saw its popularity wane in November, slipping into fourth place. David Brenchley looks at whet...
02/12/2016 - 17:30 StockMarketWire
Simon Dingemans, Financial Director, exercised 216 shares in the company on the 1st December 2016 at a price of 1247.00p. ...
02/12/2016 - 15:49 RNS
RNS Number: 8685Q GlaxoSmithKline PLC 02 December 2016 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr S Dingemans b) Position/status Chief Financial Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market partic...
02/12/2016 - 14:28 StockMarketWire
GlaxoSmithKline and Innoviva have announced the filing by GSK of a regulatory submission with the European Medicin...
02/12/2016 - 14:19 RNS
RNS Number: 8557Q GlaxoSmithKline PLC 02 December 2016 Issued: Friday, 2 December 2016, London UK - LSE Announcement GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by G...
02/12/2016 - 07:24 StockMarketWire
GlaxoSmithKline and Innoviva, have announced that the Japanese Ministry of Health, Labour and Welfare has approved ...
02/12/2016 - 07:01 RNS
RNS Number: 7952Q GlaxoSmithKline PLC 02 December 2016 Issued: Friday 2 December 2016, London UK Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved...
01/12/2016 - 11:00 RNS
RNS Number: 7064Q GlaxoSmithKline PLC 01 December 2016 GlaxoSmithKline plc Total Voting Rights and Capital In conformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital as at 30 November 2016 consisted of 5,367,734,859 ordinary shares of 25 p...
|Dividend yield||5.413 %|
Latest discussion posts More
“update from beaufort: https://www.research-tree.com/research/breakfast-today/e68cf8b2-1e9e-49a6-9007-45bbab47c279”▼
“Added at the open and yesterday, now above my intended holding %, however longer term this is beginning to look compelling. Good to see the Japan news, my better half ...”▼
“This is the second significant announcement from GSK in a ...”▼
Codes & Symbols
|Symbols||GSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK|